← Leaderboards
Brenton Scott
Pulmotect, Inc
$7,025,093
Attributed
$7,025,093
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2011–17$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$7,025,093 · 7
By mechanism
R44$6,270,701 · 4
R43$754,392 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cancer Patient”
- David Heimbrook · Leidos Biomedical Research, Inc.$436,176,488
- Larry Arthur$370,429,903
- Norman Wolmark · Nsabp Foundation, Inc.$324,028,859
- Gregory H Reaman · National Childhood Cancer Foundation$270,366,096
- Leonard Freedman · Leidos Biomedical Research, Inc.$268,085,841
- Richard A Gibbs · Baylor College Of Medicine$240,560,484
Research focus
Cancer PatientLeadCommunicable DiseasesPreventPharmaceutical PreparationsPathogenSafetyImmunocompromised HostImmunityTechnologyNovel TherapeuticsLungBreathingVirusMarketingDesignImmune SystemFundingVirus DiseasesDosePneumoniaViralClinical TrialsIn Vivo
Grant awards (10)
Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant$998,771
R44 · FY2017 · HL · contact PI
Preventing and treating RSV pneumonia in immunocompromised cancer patients$999,372
R44 · FY2016 · HL · contact PI
Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant$998,771
R44 · FY2016 · HL · contact PI
Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant$982,488
R44 · FY2015 · HL · contact PI
Preventing asthma exacerbations by reducing viral respiratory infections$985,628
R44 · FY2014 · HL · contact PI
Rapidly boosting innate immunity in the lungs to protect against pneumonia$308,146
R44 · FY2014 · AI · contact PI
Boosting the innate immune system of the lungs to prevent and treat respiratory v$231,348
R43 · FY2014 · HL · contact PI
Rapidly boosting innate immunity in the lungs to protect against pneumonia$997,525
R44 · FY2013 · AI · contact PI
Preventing asthma exacerbations by reducing viral respiratory infections$301,296
R43 · FY2012 · HL · contact PI
Rapidly boosting innate immunity in the lungs to protect against pneumonia$221,748
R43 · FY2011 · AI · contact PI